Journal article

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

Olga Kondrashova, Monique Topp, Ksenija Nesic, Elizabeth Lieschke, Gwo-Yaw Ho, Maria Harrell, Giada Zapparoli, Alison Hadley, Robert Holian, Emma Boehm, Valerie Heong, Elaine Sanij, Richard B Pearson, John J Krais, Neil Johnson, Orla McNally, Sumitra Ananda, Kathryn Alsop, Karla J Hutt, Scott H Kaufmann Show all

Nature Communications | NATURE PUBLISHING GROUP | Published : 2018

Grants

Awarded by National Health and Medical Research Council (NHMRC Australia)


Awarded by Victorian Cancer Agency


Awarded by NHMRC


Awarded by National Breast Cancer Foundation


Awarded by National Institute of Health


Awarded by Stand Up To Cancer-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant


Awarded by U.S. Army Medical Research and Materiel Command


Awarded by The Cancer Foundation of Western Australia


Awarded by National Health and Medical Research Council of Australia (NHMRC)


Funding Acknowledgements

We thank Dr. M. Herold for the Cas9/CRISPR vectors used to generate PEO4 RAD51C KO, and T. Phuong, S. Stoev, R. Hancock, K. Barber, and C. Mitchell for technical assistance. We also thank Dr. Michael Christie for reviewing the archival BRCA1-methylated HGSOC samples. The AOCS also acknowledges the contribution of the study nurses, research assistants, and all clinical and scientific collaborators to the study. The complete AOCS Study Group can be found at www.aocstudy.org. We would like to thank all of the women who participated in these research programs. This work was supported by fellowships and grants from the National Health and Medical Research Council (NHMRC Australia; Fellowship to KJH (#494836), Project grant 1062702 (CLS)); the Stafford Fox Medical Research Foundation (CLS); Cancer Council Victoria (Sir Edward Dunlop Fellowship in Cancer Research to CLS); the Victorian Cancer Agency (Clinical Fellowships to CLS CRF10-20, CRF16014); Monash University (PhD Scholarship to MT); CRC for Cancer Therapeutics (PhD top-up scholarship to MT, GH); Research Training Program Scholarship (PhD Scholarship to KN, GH); Bev Gray Ovarian Cancer Scholarship (PhD top-up scholarship to KN, VH); NHMRC Scholarship (1076048 to AH) the National Breast Cancer Foundation (PS-15-048 to AD) and the National Institute of Health (2P50CA083636) (to EMS) and the Wendy Feuer Ovarian Cancer Research Fund (to EMS). The Olivia Newton-John Cancer Research Institute acknowledges the support of the Victorian Government Operational and Infrastructure Support Program. This work was made possible through the Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. We thank Clovis Oncology for funding Foundation Medicine analyses and providing rucaparib for in vivo experiments. Funding was provided by a Stand Up To Cancer-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant (grant number SU2C-AACR-DT16-15 to EMS and SHK). Stand Up to Cancer is a programme of the Entertainment Industry Foundation; research grants are administered by the American Association for Cancer Research, a scientific partner of Stand Up To Cancer. The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Council Tasmania and The Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182), and the National Health and Medical Research Council of Australia (NHMRC; ID400413 and ID400281). The Australian Ovarian Cancer Study gratefully acknowledges additional support from S. Boldeman, the Agar family, Ovarian Cancer Action (UK), Ovarian Cancer Australia and the Peter MacCallum Foundation.